Clinical implications of reversal agents for direct oral anticoagulants
| Autor: | Vinai Bhagirath, Sarah R Monagle, Kuan H. Ng, John W. Eikelboom |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
medicine.drug_mechanism_of_action Pyridines Pyridones Factor Xa Inhibitor Hemorrhage 030204 cardiovascular system & hematology Antibodies Monoclonal Humanized Arginine Antithrombins Piperazines Dabigatran 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Rivaroxaban Edoxaban medicine Humans 030212 general & internal medicine Intensive care medicine business.industry Anticoagulants Idarucizumab Venous Thromboembolism Recombinant Proteins Thiazoles chemistry Direct thrombin inhibitor Anesthesia Factor Xa Pyrazoles Molecular Medicine Apixaban Cardiology and Cardiovascular Medicine business Factor Xa Inhibitors medicine.drug Andexanet alfa |
| Zdroj: | Future Cardiology. 13:153-159 |
| ISSN: | 1744-8298 1479-6678 |
| DOI: | 10.2217/fca-2016-0070 |
| Popis: | Direct oral anticoagulants (DOACs) are effective in preventing and treating venous thromboembolism, and preventing stroke in atrial fibrillation. Until recently, there has been no specific reversal agent for DOACs. Now, a specific antidote for the direct thrombin inhibitor, dabigatran has been approved for use, and antidotes for factor Xa inhibitors (rivaroxaban, apixaban and edoxaban) are being developed. We review the evidence for currently used and emerging reversal strategies, and discuss possible clinical implications, including increased prescription of DOACs, use of DOACs in clinical situations previously felt to pose too great a risk of bleeding, and use of reversal agents beyond currently approved indications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|